In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations
Pharmaceutics · 06.09.2023 · 15 (9) · 2287
DOI: 10.3390/pharmaceutics15092287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.09.2023. Verfasst von Changzhi Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, Shenyang 110016, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liaoning Pan Deng Xue Zhe Scholar, the National Natural Science Foundation of China, the Overseas Expertise Introduction Project for Discipline Innovation ("111Project").
Abstract (Originalsprache)
Respiratory antibiotics delivery has been appreciated for its high local concentration at the infection sites. Certain formulation strategies are required to improve pulmonary drug exposure and to achieve effective antimicrobial activity, especially for highly permeable antibiotics. This study aimed to investigate lung exposure to various inhalable ciprofloxacin (CIP) formulations with different drug release rates in a rat model. Four formulations were prepared, i.e., CIP-loaded PLGA micro-particles (CHPM), CIP microcrystalline dry powder (CMDP), CIP nanocrystalline dry powder (CNDP), and CIP spray-dried powder (CHDP), which served as a reference. The physicochemical properties, drug dissolution rate, and aerosolization performance of these powders were characterized in vitro. Pharmacokinetic profiles were evaluated in rats. All formulations were suitable for inhalation (mass median aerodynamic diameter < 5 µm). CIP in CHPM and CHDP was amorphous, whereas the drug in CMDP and CNDP remained predominantly crystalline. CHDP exhibited the fastest drug release rate, while CMDP and CNDP exhibited much slower drug release. In addition, CMDP and CNDP exhibited significantly higher in vivo lung exposure to CIP compared with CHDP and CHPM. This study suggests that lung exposure to inhaled drugs with high permeability is governed by drug release rate, implying that lung exposure of inhaled antibiotics could be improved by a sustained-release formulation strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, Wenhua Road No. 103, Shenyang 110016, China.
- Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Changzhi Shi, Sandra Cvijić, Mingshi Yang
Förderung
- Liaoning Pan Deng Xue Zhe Scholar
- the National Natural Science Foundation of China
- the Overseas Expertise Introduction Project for Discipline Innovation ("111Project")
- the Guiding Project for Science and Technology of Liaoning Province
- Ministry of Education Chunhui Program
- National Natural Science Foundation of China
- Overseas Expertise Introduction Project for Discipline Innovation (“111Project”)
- National Natural Science Foundation of Liaoning
Zitieren
APA
Shi, C., Guo, K., Zhang, L., Guo, Y., Feng, Y., Cvijić, S., Cun, D., & Yang, M. (2023). In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. Pharmaceutics, 15(9), 2287. https://doi.org/10.3390/pharmaceutics15092287
Vancouver
Shi C, Guo K, Zhang L, Guo Y, Feng Y, Cvijić S, et al. In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. Pharmaceutics. 2023;15(9):2287. doi:10.3390/pharmaceutics15092287
BibTeX
@article{Shi2023,
author = {Shi, Changzhi and Guo, Kewei and Zhang, Li and Guo, Yi and Feng, Yu and Cvijić, Sandra and Cun, Dongmei and Yang, Mingshi},
title = {In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {9},
pages = {2287},
doi = {10.3390/pharmaceutics15092287}
}
EUVIMED